Novel Targets in the Ovarian Cancer Treatment Paradigm | Supplements and Featured Publications

March 31, 2022

Investigators are hoping to dramatically improve the platinum-resistant ovarian cancer treatment paradigm with the development of the first-in-class antibody-drug conjugate upifitamab rilsodotin.

March 12, 2022

Michael J. Birrer, MD, PhD, discussed remaining questions when addressing platinum-sensitive ovarian cancer.

March 11, 2022

Michael Birrer, MD, PhD, discusses how new technology has transformed ADCs, how upifitamab rilsodotin could have a role in treating patients with ovarian cancer, and why the NaPi2B biomarker could be a vital target.

February 04, 2022

Debra L. Richardson, MD, FACS, FACOG, discusses the role of NaPi2b as a target for upifitamab rilsodotin, data that have emerged from the ongoing phase 1/2 UPLIFT trial, and the development of other studies like UPNEXT and UPGRADE that are further evaluating upifitamab rilsodotin in patients with ovarian cancer.

February 02, 2022

Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.

January 31, 2022

Bradley J. Monk, MD, FACS, FACOG, discusses the unmet needs for patients with ovarian cancer and the clinical trials that seeking to address those needs, including the ADC upifitamab rilsodotin.

January 05, 2022

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

January 03, 2022

Bradley J. Monk, MD, FACS, FACOG, discusses existing unmet needs in the treatment of patients with recurrent ovarian cancer.